Rising Costs in Prescription Drugs and the Role of Biosimilars
The most rapidly growing area of health care spending is on prescription medications. At the forefront are biologics, which can cost up to $200,000 annually. There are “generic” alternatives known as biosimilars that have the potential to save Americans billions, yet their adoption is stymied by unnecessary bureaucratic hurdles. We are working to reform this broken system to lower drug prices for Americans.
While initial constraints for biosimilars were established by Congress, the FDA has historically been overly cautious. For instance, the FDA mandates that biosimilar developers perform comparative clinical studies—a requirement not imposed on other generic medications. So far, these studies have largely proven ineffective compared to more efficient methods for assessing compatibility. Given the years it takes and the average cost of $24 million, it seems pragmatic to eliminate this requirement to expedite the entry of more biosimilars into the market.
Since the approval of the first biosimilars in 2015, patient access has been challenging. When doctors prescribe costly biologics, switching to biosimilars isn’t common practice, much like with other brand-name drugs and their generics. This unusual system benefits drug companies, pharmacy benefit managers, and reimbursement policies that favor pricier medications.
At present, the FDA is actively working to simplify the replacement of high-cost biological products with biosimilars. We intend to unveil new policies designed to streamline the biosimilar process dramatically, significantly reducing both the time and costs associated with bringing these lower-cost alternatives to market.
Currently, only 77 biosimilars have received approval in the U.S., which represents a tiny fraction of approved biologics that have “generic” counterparts. In stark contrast, there are over 30,000 approved generic drugs, far outnumbering brand-name options. By 2024, nearly 90% of non-biological prescriptions filled in the U.S. will be for generic drugs.
When we began evaluating the situation about seven months ago, it was clear how critical the landscape had become for biosimilar developers. Even though biologics account for 51% of drug spending in the U.S., only 10% of those facing patent expiration in the next decade are in the biosimilar development stage. To foster more biosimilar development, we should remove the cumbersome requirements that hinder progress.
Currently, it takes six to eight years for biosimilars to reach the market, allowing biopharmaceutical firms to maintain high prices for a longer time. Bureaucratic processes also limit how many biosimilars can enter the market. Typically, if only one or two competing biosimilars exist, the prices remain elevated. This dynamic benefits a select few. We need to cut through the regulatory red tape to promote genuine competition.
Our reforms aim to tackle a fundamental issue within health care: the lack of competition contributing to years of rising costs. These market inefficiencies have led to an affordability crisis affecting all insurance programs.
A report from the Accessible Medicines Association indicated that biosimilars might save the nation $20 billion in 2024 alone. Our reforms are set to enhance these annual savings and may yield billions for the Medicare program. For biosimilar developers, bypassing extra clinical trials could potentially lower overall development costs by 25% to 30%.
Some advocates for the pharmaceutical industry may resist this regulatory easing. However, the administration is dedicated to prioritizing the interests of the public. We’ve demonstrated that, through initiatives like “most-favored-nation” pricing, we can encourage necessary reforms while promoting innovation. The goal is to establish regulatory processes that defend innovation while ensuring affordable solutions for the public.
We’re also working collaboratively to expedite FDA reviews for life-changing medications and to coordinate quick reimbursement processes for Medicare and Medicaid.
Politicians can continue to discuss reforms while pouring resources into a flawed system. Secretary of Health and Human Services Robert F. Kennedy, Jr. has introduced the “Make America Healthy Again” agenda to address crucial issues like drug adequacy. Ultimately, the most effective way to reduce drug expenses is to eliminate unnecessary medications.
Now is the time for meaningful reforms to ensure fair pricing in health care. Generic drugs have successfully saved Americans trillions over the years, making vital treatments more affordable for many. We aim to achieve similar results with biosimilars.
